A review of the cardiovascular safety and potential benefits of incretin-based therapies for patients with type 2 diabetes mellitus.
Peter h. Jones, MD, FACP, FNLA
Advertisement
Articles by Peter h. Jones, MD, FACP, FNLA
Advertisement
Latest Updated Articles
- The Cardiovascular Safety of Incretin-Based Therapies
February 3rd 2014
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5